Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 9,367 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Contraception
Interventions: Ovaprene; Device
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 656 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Obesity
Interventions: qigong, acupressure-TAT; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Leukemia
Interventions: aldesleukin; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 104
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more

Conditions: Atopic Dermatitis
Interventions: emollient (Cetaphil cream); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Up to 1 Month
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Muscle Wasting, Non Small Cell Lung Cancer
Interventions: GTx-024, placebo; Drug
Lead sponsor: GTx; Industry
Eligibility: 30 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Long Beach, California • Aventura, Florida + 24 more

Conditions: Non Small Cell Lung Cancer, Solid Tumor
Interventions: BBP-398 with nivolumab; Drug
Lead sponsor: Navire Pharma Inc., a BridgeBio company; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more

Conditions: Multiple Sclerosis
Interventions: Fampridine-SR, Placebo; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Papulopustular Rosacea
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 38
States / cities: Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more

Conditions: Deep Vein Thrombosis, Post-thrombotic Syndrome
Interventions: EkoSonic® Endovascular System, Alteplase; Device · Biological
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 22
States / cities: Los Angeles, California • Aurora, Colorado • Darien, Connecticut + 18 more

Conditions: Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Malignant Digestive System Neoplasm, Rectal Carcinoma, Small Intestinal Carcinoma
Interventions: PAGODA algorithm, Oxaliplatin, Folinic Acid, Fluorouracil; Other · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 390
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more

Conditions: Primary Fibromyalgia
Interventions: TNX-102 SL Tablet 2.8 mg; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 30 more

Conditions: Hypertension
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 407
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more

Conditions: Neurocognitive Dysfunction
Interventions: Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Progressive Supranuclear Palsy, Parkinson's Disease
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Refractory Differentiated Thyroid Gland Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib; Procedure · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 307
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 110
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more

Conditions: Major Depressive Disorder
Interventions: MIN-117 5.0 mg, MIN-117 2.5 mg, Placebo; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Little Rock, Arkansas • Garden Grove, California • Torrance, California + 7 more

Conditions: Advanced Solid Tumors
Interventions: AMG 650; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more

Conditions: X-Linked Myotubular Myopathy
Interventions: ASP2957, Methylprednisolone, Prednisolone, Sirolimus; Genetic · Drug
Lead sponsor: Astellas Gene Therapies; Industry
Eligibility: Up to 36 Months · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: apricoxib, Placebo, Docetaxel or Pemetrexed; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Opioid Dependence, Substance Abuse Disorders, Complex Medical Patients, Primary Care Patients With Chronic Conditions
Interventions: MOUD "Plus" Intervention (treatment as usual + coordinated counseling and referral to community based peer), Treatment As Usual (primary care with low threshold MOUD prescribing); Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Contraceptive Efficacy Study of Ovaprene

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Study of Two Complementary and Alternative Medical Treatments for Maintenance of Weight Loss

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

Postural Instability in Progressive Supranuclear Palsy

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care